Marianne Doazan1, Stéphane Hans2, Sylvain Morinière3, Benjamin Lallemant4, Sébastien Vergez5, Karine Aubry6, Erwan De Monès7, Florent Espitalier8, Franck Jegoux9, Pierre Pradat10, Philippe Céruse1,11. 1. Department of Head and Neck Surgery, Hospices Civils de Lyon, University Hospital Lyon-Nord, Lyon, France. 2. Department of Head and Neck Surgery, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France. 3. Department of Head and Neck Surgery, University Hospital Bretonneau, Tours, France. 4. Department of Head and Neck Surgery, University Hospital Carémeau, Nîmes, France. 5. Department of Head and Neck Surgery, University Hospital Rangueil-Larrey, Toulouse, France. 6. Department of Head and Neck Surgery, University Hospital Dupuytren, Limoges, France. 7. Department of Head and Neck Surgery, University Hospital Pellegrin, Bordeaux, France. 8. Department of Head and Neck Surgery, University Hospital Hôtel-Dieu, Nantes, France. 9. Department of Head and Neck Surgery, University hospital Pontchaillou, Rennes, France. 10. Clinical Research Committee, Hospices Civils de Lyon, University Hospital Lyon-Nord, France. 11. Université Claude Bernard, Lyon, France.
Abstract
BACKGROUND: Transoral robotic surgery (TORS) is an option to treat supraglottic squamous cell carcinomas (SCCs). We studied the oncologic outcomes after TORS for supraglottic laryngectomy (SGL). METHODS: We conducted a multicenter observational study of SGL using TORS for patients with supraglottic SCC with at least 2 years of follow-up. RESULTS: One hundred twenty-two patients were included in our study. Mean follow-up was 42.8 months. Local control was 94.3% at 2 years and 90.2% at 5 years. Overall survival and disease-free survival were 86.9% and 95.1% at 2 years, and 78.7% and 94.3% at 5 years, respectively. Sixty-three patients (51.6%) received adjuvant radiotherapy. For 16 of them, this was due to close or positive margins. CONCLUSION: Local control rate after TORS SGL was at least equivalent to what has been described in the literature for open or transoral laser surgery, or with radiotherapy. Using TORS seems to be an effective therapeutic treatment of early-stage and intermediate-stage supraglottic SCCs.
BACKGROUND: Transoral robotic surgery (TORS) is an option to treat supraglottic squamous cell carcinomas (SCCs). We studied the oncologic outcomes after TORS for supraglottic laryngectomy (SGL). METHODS: We conducted a multicenter observational study of SGL using TORS for patients with supraglottic SCC with at least 2 years of follow-up. RESULTS: One hundred twenty-two patients were included in our study. Mean follow-up was 42.8 months. Local control was 94.3% at 2 years and 90.2% at 5 years. Overall survival and disease-free survival were 86.9% and 95.1% at 2 years, and 78.7% and 94.3% at 5 years, respectively. Sixty-three patients (51.6%) received adjuvant radiotherapy. For 16 of them, this was due to close or positive margins. CONCLUSION: Local control rate after TORS SGL was at least equivalent to what has been described in the literature for open or transoral laser surgery, or with radiotherapy. Using TORS seems to be an effective therapeutic treatment of early-stage and intermediate-stage supraglottic SCCs.
Authors: Jérôme R Lechien; Robin Baudouin; Marta P Circiu; Carlos M Chiesa-Estomba; Lise Crevier-Buchman; Stephane Hans Journal: Eur Arch Otorhinolaryngol Date: 2022-06-22 Impact factor: 3.236
Authors: À Roselló; R Albuquerque; X Roselló-Llabrés; A Marí-Roig; A Estrugo-Devesa; J López-López Journal: Med Oral Patol Oral Cir Bucal Date: 2020-09-01
Authors: Anthony T Nguyen; Michael Luu; Jon Mallen-St Clair; Alain C Mita; Kevin S Scher; Diana J Lu; Stephen L Shiao; Allen S Ho; Zachary S Zumsteg Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: Christian Simon; Avinash Beharry; Vinidh Paleri; Pascaline Dübi; Karma Lambercy; F Christopher Holsinger; Jelena Todic Journal: Head Neck Date: 2022-06-02 Impact factor: 3.821
Authors: Felix Boehm; Rene Graesslin; Marie-Nicole Theodoraki; Leon Schild; Jens Greve; Thomas K Hoffmann; Patrick J Schuler Journal: Cancers (Basel) Date: 2021-03-19 Impact factor: 6.639